This Article Full Text (PDF) All Versions of this Article: 1076029608319441v1 15/4/428    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Elalamy, I. Articles by Chapuis, F. PubMed PubMed Citation Articles by Elalamy, I. Articles by Chapuis, F. Social Bookmarking                         What's this?

Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France

Service d'Hématologie Biologique; Hôpital Tenon UPMC, Paris France

Gregoire Le Gal, MD

Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest

Fatima Nachit-Ouinekh, PhD

Cemka Eval, Bourg la Reine, Fatima.f.nachit{at}gsk.com

Antoine Lafuma, MD

Cemka Eval, Bourg la Reine

Corinne Emery, MSc

Cemka Eval, Bourg la Reine

Camille Le-Fur, Pharm

GlaxoSmithKline, Marly-Le-Roi

François Chapuis, MD, PhD

Universite Lyon 1; Hospices Civils de Lyon, Unite de Recherche Clinique Recif Pimer, France

Heparin-induced thrombocytopenia is a severe drug adverse effect with possible dramatic consequences. The risk is 0.1% to 5%. The costs of heparin-induced thrombocytopenia in France were estimated using the Programme Médicalisé des Systèmes d’Information (PMSI) national discharge database. Hospitalizations with heparin-induced thrombocytopenia were identified using diagnostic codes. Costs were assessed from the perspective of the French Sickness Fund or hospitals. Heparin-induced thrombocytopenia could be the reason of admission or could occur during the stay and lead to a different tariff or to additional costs associated with extra length of stay. Direct costs were also estimated from experts’ opinions. A sensitivity analysis was performed from data collected in 1 center. During 2005, 445 hospitalizations with heparin-induced thrombocytopenia codes were identified. For 45 patients, the main diagnosis was heparin-induced thrombocytopenia; for the remaining 400 patients, heparin-induced thrombocytopenia occurred during the hospital stay. Tariffs and extra costs were used to estimate an overall average cost of 3230 for heparin-induced thrombocytopenia. For patients with heparin-induced thrombocytopenia as main diagnosis, the average cost was 3400; for the patients with heparin-induced thrombocytopenia that occurred during the stay, 1910 was due to an increased of the tariff and 3348 to an increased length of stay. Estimated direct costs of an episode were 3350 to 3700. Different methods were used to arrive at an estimated cost of 3500 for a heparin-induced thrombocytopenia episode for inpatients. One limitation of the study is that heparin-induced thrombocytopenia tends to be underreported by physicians during hospitalization.

Key Words: thrombocytopenia • cost • heparin

This version was published on August 1, 2009

Clinical and Applied Thrombosis/Hemostasis, Vol. 15, No. 4, 428-434 (2009)
DOI: 10.1177/1076029608319441


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?